If you are building a long-term investment portfolio, focusing on high-quality ASX 200 shares with strong growth drivers can be a smart approach.

The best opportunities are often found in businesses with scale, strong management, and exposure to trends that can support earnings growth over many years.

Here are two ASX 200 shares that could be worth considering for the next five years.

ResMed Inc (ASX: RMD)

The first ASX 200 share that could be worth considering for the next five years is ResMed.

The sleep technology company is a global leader in devices and digital platforms used to treat sleep apnoea and other respiratory conditions. Its ecosystem combines medical devices, software, and cloud-connected data to help patients manage sleep-related health issues.

One of the most compelling aspects of the investment case is the size of the market opportunity. More than one billion people globally are estimated to suffer from sleep apnoea, yet a large portion of patients remain undiagnosed or untreated.

This underpenetrated market could provide a long runway for growth as awareness improves and diagnostic technology becomes more accessible. At the same time, wearable technology and digital health tools are helping identify more potential patients who may require treatment.

With strong global market leadership, a growing digital health ecosystem, and a massive addressable market, ResMed appears well positioned to continue expanding over the coming years.

Wesfarmers Ltd (ASX: WES)

Another ASX 200 share that could be worth considering by Aussie investors for the next five years is Wesfarmers.

The company is one of Australia’s leading conglomerates, with a portfolio of well-known businesses including Bunnings, Kmart, Priceline, Target, and Officeworks. These brands have strong market positions and generate consistent cash flow, providing a solid foundation for the group.

One of Wesfarmers’ key strengths is its disciplined capital allocation. Management has a track record of investing in growth opportunities while also returning capital to shareholders when appropriate.

In addition, the company has been investing in areas such as lithium and health, which could provide new avenues for growth beyond its core retail operations.

With a combination of defensive earnings from its retail businesses and optionality through new investments, Wesfarmers appears well placed to deliver steady returns over the next five years. This could make it worthy of a spot in a balanced investment portfolio.

The post 2 fantastic ASX 200 shares to buy and hold for the next five years appeared first on The Motley Fool Australia.

More reading

• Why I’d buy these high-quality ASX 200 shares this week
• $20,000 of Wesfarmers shares can net me $820 in passive income!
• 3 dependable ASX shares to add to a superannuation fund in 2026
• How to build $100,000 a year in passive income from ASX shares
• Pulse check: How are the top 10 ASX 200 shares performing amid a new war?

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX All Ords gold stock St Barbara Ltd (ASX: SBM) has smashed the returns delivered by the All Ordinaries Index (ASX: XAO) over the past year.

But not today.

St Barbara shares closed on Friday trading for 57.5 cents. In early morning trade on Monday, shares are changing hands for 54.5 cents apiece, down 5.2%.

For some context, the All Ords is down 2% at this same time, while the S&P/ASX All Ordinaries Gold Index (ASX: XGD) is down a steeper 4.7%.

Despite today’s retrace, shares in the ASX All Ords gold stock remain up 147.7% since this time last year, racing ahead of the 3.7% 12-month gains delivered by the All Ords.

Atop ongoing pressure in the gold price, here’s what investors are mulling over today.

ASX All Ords gold sinks amid project update

St Barbara shares are sliding today despite a positive update on the miner’s New Simberi Gold Project, located in Papua New Guinea.

The ASX All Ords gold stock said it expects to complete both the Lingbao and Kumul transactions in the first days of April. The Final Investment Decision (FID) on Simberi will then be triggered on the same date.

At completion, St Barbara will receive a $370 million cash payment from Lingbao.

Commenting on the progress, St Barbara CEO Andrew Strelein said, “The receipt of Lingbao’s approval from Chinese and PNG regulators is very positive step and satisfies a key condition precedent in completion of the transactions.”

Strelein added:

The parties have been targeting the end of March quarter for completion and St Barbara remains confident the remaining conditions will be met to allow completion on track in the first days of April 2026 and declaring Final Investment Decision on the New Simberi Gold Project.

Energy update

Amid the rising global energy crisis fuelled by the war in Iran, St Barbara also sought to ease investor concerns about its diesel requirements.

The ASX All Ords gold stock revealed it had received various inquiries about Simberi’s fuel stocks, given the impact on global diesel supply chains amid the attacks on tankers in the Strait of Hormuz.

The gold miner noted that its Simberi project is “well stocked” with diesel fuel.

Which is a good thing, as the Simberi Operations currently use some 65,000 litres per day of diesel for the mining fleet and power generation.

According to the release:

Current diesel supply stored on Simberi Island is approximately 4.7 million litres (sufficient to cover more than two months’ usage), with another 3.5 million litres in allocated storage in country at Lae and Port Moresby storage locations.

Pleasingly, St Barbara noted that the majority of its diesel stockpile was paid for based on average January (pre-conflict) pricing.

The post Up 148% in a year, ASX All Ords gold stock sinking today amid $370 million news appeared first on The Motley Fool Australia.

More reading

• 2 top ASX shares I’d buy today amid falling prices
• 2 fantastic ASX 200 shares to buy and hold for the next five years
• Expert names 2 ASX ETFs to buy now
• Why JB Hi-Fi shares are a retiree’s dream
• These ASX dividend shares pay 7% and could jump 25%

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Exchange-traded funds (ETFs) continue to grow in popularity with investors.

In light of this, there’s no shortage of options for Australian investors to choose from.

To narrow things down, let’s see what one analyst is recommending this week, courtesy of The Bull. Here’s what you need to know:

Munro Global Growth Fund Complex ETF (ASX: MAET)

DP Wealth Advisory is positive on the Munro Global Growth Fund Complex ETF.

It aims to smooth the investment journey through utilising capital preservation tools such as increased cash levels, shorts, put options, currency hedging, and equity exposure management. It gives investors access to an actively managed portfolio of 30-50 global growth stocks.

The advisory firm notes that it has a strong track record and positive outlook. It explains:

Funds under management, including its unlisted managed fund, exceed $1 billion. This exchange traded fund focuses on global companies involved in high performance computing, digital enterprise, climate, innovative health and security.

Also, the ETF focuses on capital preservation. Main investments in its February 2026 report included Nvidia, TSMC, Amazon and Alphabet. During the past five years, the fund has returned 9.1 per cent per annum. I hold MAET in my self managed super fund. I like the fund’s historical record and outlook.

BetaShares S&P/ASX Australian Technology ETF (ASX: ATEC)

Another ASX ETF that DP Wealth Advisory is positive on is the BetaShares S&P/ASX Australian Technology ETF.

This fund provides investors with access to a group of Australian tech shares, including WiseTech Global Ltd (ASX: WTC) and Xero Ltd (ASX: XRO).

With ASX tech shares down heavily over the past 12 months, dragging this ETF down with them, DP Wealth Advisory appears to see now as an opportune time for investors to initiate a position in the fund.

Commenting on the BetaShares S&P/ASX Australian Technology ETF, its analyst said:

This exchange traded fund invests in Australian technology companies. Across global exchanges, technology companies have been under pressure in response to the interruption and impact of artificial intelligence.

Companies held in this ETF include Computershare, WiseTech Global and Xero. Performance has been sub-optimal in the past 12 months, but has returned more than 9 per cent per annum in the past three years. ATEC had net assets of more than $483 million at March 18, 2026. An opportunity exists on a weaker share price and potentially improving technology stocks moving forward.

The post Expert names 2 ASX ETFs to buy now appeared first on The Motley Fool Australia.

More reading

• 3 exciting ASX ETFs for Aussie growth investors to buy and hold
• ASX ETFs that target undervalued sectors
• 5 fantastic ASX ETFs to buy and hold for five years
• Have ASX technology shares finally hit rock bottom?
• 3 ASX ETFs down 25% that could be big long-term winners

Motley Fool contributor James Mickleboro has positions in WiseTech Global and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Nvidia, Taiwan Semiconductor Manufacturing, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended Alphabet, Amazon, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

JB Hi-Fi Ltd (ASX: JBH) shares may be a very underrated pick at this time for retirees.

An ASX retail share may not seem like the most compelling business for dividend income or long-term returns.

But, the owner of JB Hi-Fi Australia, JB Hi-Fi New Zealand, The Good Guys and E&S actually has a number of positives, including an incredible dividend record.

Let’s take a look at what makes it so appealing.

Excellent dividend record for retirees

JB Hi-Fi has an excellent dividend record for an ASX retail share. Looking back, it has increased its dividend almost every year since 2013, aside from a slight reduction in FY23, which is understandable considering the headwind of high inflation and rising interest rates.

In the recent FY26 half-year result, the business increased its interim dividend per share by 23.5% to $2.10 per share. HY26’s growth was partly because of earnings growth and partly due to an increase in the dividend payout ratio, going from 65% of net profit to 75% (thanks to its increased dividend payout guidance range of between 70% to 80%).

JB Hi-Fi said that it continues to maintain a strong balance sheet and will continue to regularly review its capital structure with a focus on “maximising returns to shareholders and maintaining balance sheet strength and flexibility”.

The current forecast on Commsec suggests the business could pay an annual dividend per share of $3.42 in FY26. That translates into a grossed-up dividend yield of 6.8% (including franking credits) at the time of writing, which I think would be a great starting yield for retirees.

Good growth potential

I’d describe JB Hi-Fi as the best electronics retailer in Australia. It has a number of competitive advantages including its scale, multiple brands, low cost operating model, multichannel approach and its people.

I think it’s those factors that help the business stay ahead of others, deliver solid margins and grow its market share.

The business continues to grow its sales, with solid progress in January 2026. JB Hi-Fi Australia sales increased 4% and The Good Guys sales grew 2.7% year over year.

I also think JB Hi-Fi has more defensive earnings than some investors may give it credit for, with demand for smartphones, laptops and appliances being somewhat consistent.

This could be a good time to invest for retirees because the JB Hi-Fi share price has declined by around 40% over the past six months and more than 25% in the year to date (at the time of writing).

It’s now trading at under 16x FY26’s estimated earnings, which seems good value to me.

The post Why JB Hi-Fi shares are a retiree’s dream appeared first on The Motley Fool Australia.

More reading

• Guess which ASX 200 stock could be worth $90 a share
• 5 things to watch on the ASX 200 on Monday
• JB Hi-Fi vs. Harvey Norman: Which is the better retail buy?
• A once-in-a-decade chance to earn a supersized passive income from ASX shares?
• 3 top ASX dividend share buys for passive income in March

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Income investors are always scanning for reliable ASX dividend shares. But finding stocks that offer both high yield and growth potential? That’s where things get trickier.

Two ASX dividend shares stand out right now: Perpetual Ltd (ASX: PPT) and Shaver Shop Group Ltd (ASX: SSG). Both deliver attractive yields around 7%, and brokers see meaningful upside ahead.

Let’s take a closer look.

Perpetual: Sharpen execution, unlock value

Perpetual is a well-known financial services group, operating across asset management, wealth management, and corporate trust. But the ASX dividend share is undergoing a major shift.

Last week, the company announced the $500 million sale of its wealth business to Bain Private Equity. The move is all about simplification. By narrowing its focus, Perpetual aims to sharpen execution and unlock value.

Management of the ASX dividend share says proceeds will be used to reduce debt and invest in organic growth across its remaining divisions. That’s a positive signal for dividend sustainability.

Perpetual has a long-standing reputation in funds management and a solid institutional footprint. The business is becoming leaner, which could improve margins over time.

However, earnings can be sensitive to market movements. Funds under management can fluctuate, and execution risk remains as the company reshapes itself.

This ASX dividend share shines when dividend payouts come into play. Analysts at Macquarie expect a 7% dividend yield this financial year, easing slightly to 6.7% in FY27 and 6.4% in FY28. That’s still comfortably above market averages.

And there’s potential capital upside too. Macquarie has a bullish price target of $24.60 on the ASX dividend share. The broader consensus sits at $20.32, about 26% above current levels.

Shaver Shop Group: Strong niche, growing online sales

Shaver Shop is one of the region’s leading retailers of personal grooming products. Think electric shavers, clippers, trimmers, and wet shave essentials. It operates 126 stores across Australia and New Zealand, alongside a growing online channel.

This is a steady, cash-generative retail business. Grooming products tend to have repeat demand, and Shaver Shop has built a strong niche. Its online sales are also gaining traction.

Recent numbers back that up. In the second half of FY26 to 22 February 2026, total sales rose 3.8%, while online sales jumped 12.7%. That kind of growth can support future earnings — and dividends.

Like all retailers, this ASX dividend share is exposed to consumer spending cycles. Cost pressures and competition could also weigh on margins.

Shaver Shop has an impressive dividend track record. It increased its dividend every year from 2017 to 2023, held steady in 2024, and nudged it higher again in FY25.

Right now, the stock offers a grossed-up yield of 10.7%, including franking credits. That’s exceptionally high.

And it’s not just about income. Analysts see upside in the share price too, with an average target of $1.71. That’s a 29% upside at current levels.

The bottom line

Perpetual and Shaver Shop tick two key boxes: strong passive income and growth potential.

They’re not risk-free. No dividend stock ever is. But with yields around 7% or higher and double-digit upside on offer, both are worth a closer look for income-focused investors.

The post These ASX dividend shares pay 7% and could jump 25% appeared first on The Motley Fool Australia.

More reading

• These 3 ASX stocks are paying better than 7% dividend yields
• How high does Macquarie think this ASX 200 stock will go after its wealth sale?
• 2 ASX shares with dividend yields above 8%
• Why Lifestyle Communities, Perpetual, Reliance Worldwide, and Woodside shares are rising today
• This ASX financial stock just struck a $500 million deal

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Shaver Shop Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are plenty of ASX shares for investors to choose from.

To narrow things down, let’s see what analysts are saying about three popular shares, courtesy of The Bull. Here’s what they are recommending:

Commonwealth Bank of Australia (ASX: CBA)

The team at Medallion is siding with the majority of brokers by declaring CBA shares as sell.

While acknowledging that CBA is the highest-quality Australian bank, it feels that its valuation is stretched.

Medallion also highlights that its shares are trading at a significant premium to peers despite having similar earnings growth outlook. It said:

CBA remains the highest quality franchise among Australia’s major banks, but the valuation now looks stretched. The stock trades on a price-to-earnings multiple well above its peers despite similar earnings growth prospects. The recent annual dividend yield around 3 per cent is modest compared with other income opportunities.

With credit growth slowing and net interest margins stabilising, we believe earnings momentum is unlikely to justify such a premium valuation. After a strong share price run, investors may want to consider taking profits and reallocating capital to more attractively valued opportunities.

QBE Insurance Group Ltd (ASX: QBE)

Over at DP Wealth Advisory, its analysts have named this insurance giant as a hold this week.

It acknowledges that QBE is a well-managed company, but has concerns over challenging trading conditions. It explains:

QBE is a well managed global business with a strong return on equity and improving profit margins. Adjusted return on equity was 19.8 per cent in full year 2025 compared to 18.2 per cent in the prior corresponding period. Gross written premiums grew 7 per cent. Insurance companies rely on investment returns, which is challenging in a volatile global market. We retain a hold recommendation given QBE is trading near a 12 month consensus valuation.

Qantas Airways Ltd (ASX: QAN)

Finally, due to the prospect of jet fuel prices steering higher for longer, the team at DP Advisory is staying clear of Qantas shares for the time being.

As a result, it has named the Flying Kangaroo as a sell this week and believes there are better options out there for investors. It said:

Qantas is a well managed domestic and international airline, holding a 70 per cent market share in Australia. The shares were trading at $10.65 on February 25, a day prior to the company posting its first half year result in fiscal year 2026. The stock was trading at $8.46 on March 19. Qantas announced on March 13, 2026 that it had settled a class action for $105 million regarding flight credits during COVID-19. The company has hedged jet fuel supply prices in the shorter term, but I’m concerned about the impact of possibly higher crude oil prices over the longer term.

I’m also mindful of the expense involved in Qantas upgrading its airline fleet after years of under investment by previous management as well as COVID-19. Qantas has a high fixed cost base. In my view, it’s a cyclical stock due to its reliance on consumer and business sentiment. Other stocks appeal more at this point.

The post Buy, hold, sell: CBA, QBE, and Qantas shares appeared first on The Motley Fool Australia.

More reading

• The stress-free ASX ETF portfolio built to weather market crashes
• Why I think now is a great time to buy Qantas shares for long-term passive income
• If you’re 55 and behind on superannuation, here’s what you can still do
• 2 ASX shares that could benefit from rising interest rates and oil prices
• Pulse check: How are the top 10 ASX 200 shares performing amid a new war?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Acrow Ltd (ASX: ACF) have been sold off over the past few weeks in particular and are now trading marginally above their 12-month lows.

The team at Shaw and Partners believes that this creates a buying opportunity for investors in the All Ords company, and they’ve issued a bullish price target on the stock, which we’ll get to later.

‘Firstly, why does Shaw like the look of this company?

Recent headwinds no big deal

The Shaw team said in a research note to clients that current headwinds, in the form of negative free cash flow and an increase in net debt, can be explained by project delays in Queensland and by investments for growth.

But they say a turnaround for Acrow could be rapid.

As they said:

Our forecasts assume a return to normal conditions in infrastructure spending across Australia and suggest that Acrow can generate positive free cash flow as early as 2H26. Potentially above-average margins from Olympics work represent upside to our forecasts.

Citi said the company had been investing via expenditure on equipment for leasing, working capital, and acquisitions, with Acrow buying four companies recently for a combined $75.4 million.

The Citi team said Acrow also remained exposed to strong-growth markets.

They said further:

These include the Industrial Access division’s significant growth opportunities in the defence and asset maintenance sectors, and the Brisbane 2032 Olympic and Paralympic Games. Regarding the Games, staged construction on venues is expected to commence in the March Qtr 2027 with peak activity across multiple venues expected between 2027 and 2031. We expect contract awards to be announced from July 2026. The 2032 hard-close date may also provide various Engineering & Construction companies the ability to surge-price for several years.

Shares looking cheap

Citi said that despite the near-term growth drivers, Acrow was trading at a discount to its peers.

Citi has a price target of $1.25 per share for Acrow, compared to its current share price of 85.5 cents, which would represent a 46.2% return.

The company also pays a trailing dividend yield of 5.78%.

Acrow in February reported record sales revenue of $155.9 million for the first half, up 23% on the previous corresponding period, while underlying net profit was 22% lower at $12.9 million.

The company’s accelerated capital expenditure during the half saw net debt increase by $28.2 million to $151.5 million, which was above the company’s target range.

Acrow was valued at $266.4 million at the close of trade on Friday.

The post Which All Ords builder could benefit from Brisbane’s big Olympics build? appeared first on The Motley Fool Australia.

More reading

• 2 top ASX shares I’d buy today amid falling prices
• 2 fantastic ASX 200 shares to buy and hold for the next five years
• Up 148% in a year, ASX All Ords gold stock sinking today amid $370 million news
• Expert names 2 ASX ETFs to buy now
• Why JB Hi-Fi shares are a retiree’s dream

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Plenty of technology shares have been sold down in recent months as uncertainty about how artificial intelligence will disrupt legacy business models spooks the market.

Some of these companies have been oversold, however, and for some, AI looks set to be a positive, allowing them to build products more cheaply and serve their customers better.

The analyst team at Citi has recently issued research notes to their clients on three ASX technology shares they think are looking cheap.

So let’s take a look.

Xero Ltd (ASX: XRO)

Citi says that its analysis of the rate of business formation and insolvencies paints a positive outlook for Xero, “with business formation accelerating in Australia and US and insolvency trends improving in Australia and New Zealand, steady in UK and increasing in US”.

The Citi team added:

While there is typically a lag between both metrics and subscriber growth and churn for Xero, we see this as positive. One question is whether AI is driving an increase in business formation – in our view, it is likely too early but is an interesting trend to watch as it could be an offset to the disruption thesis.  

Citi has a price target of $144.80 on Xero shares, compared with its current price of $77, which would represent an 88.1% return if achieved.

Seek Ltd (ASX: SEK)

The Citi team believes there are some headwinds coming for employment listings company Seek, but they still think the company is undervalued.

On the downside, Citi says job listings in Australia were down 3% year on year in February and 0.5% month on month, which they said wasn’t surprising given the rate hike in February.

The Citi team added:

After the rate hikes in February and March, Citi economists expect another hike in May due to concerns over inflation expectations. These may pose downside risk on job volumes for the remainder of FY26 and 1H27 job volumes.

Despite these moderating factors, Citi has a price target of $26 on Seek shares compared with $14.44 currently. If achieved, this would be an 80.1% return.

Block Inc (ASX: XYZ)

This company, which owns payments brands Square and CashApp, announced last month that it would slash staff numbers by 4,000 to a new headcount of 6,000.

Citi said this has been the focus of much investor attention, but in its view, the more interesting AI development would be its ability to drive product releases “leading to potential gross profit upside”.

The Citi team added:

Focusing on recent initiatives led by AI releases, our proprietary analysis shows potential gross profit growth outperformance vs consensus by about 180 basis points in 2026, about 430 basis points in 2027 and about 440 basis points in 2028, pushing consolidated GP growth to the high-teens.

Citi has a price target of US$85 on Block shares, compared to US$59.37 currently. That increase would represent a 43.2% gain.

Applied to the Australian-listed Block shares, it would mean an increase from $82.86 currently to $118.57.

The post What are the 3 ASX technology shares Citi rates as a buy at the moment? appeared first on The Motley Fool Australia.

More reading

• Down 50%: Could these 2 leading ASX tech stocks rebound big?
• 3 ASX shares I’d buy today and not check for a year
• Top brokers name 3 ASX shares to buy next week
• The best ASX shares to invest $1,000 in right now
• Why buying ASX shares in March could supercharge your wealth

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Genesis Energy Ltd (ASX: GNE) share price is in focus today after the company wrapped up a NZ$300 million fully underwritten renounceable rights offer, with the shortfall bookbuild clearing at a premium and total funds raised across all offers reaching NZ$400 million.

What did Genesis Energy report?

• Successful completion of the NZ$300 million 1 for 7.9 renounceable rights offer
• Shortfall bookbuild cleared at NZ$2.22 per new share, NZ$0.17 above application price
• Aggregate of NZ$400 million raised, including a NZ$100 million placement
• Settlement on ASX expected 24 March 2026, NZX on 25 March 2026
• New shares to rank equally with existing Genesis Energy shares
• FY25 revenue reported at NZ$3.7 billion

What else do investors need to know?

Genesis Energy’s shortfall bookbuild was well supported, delivering a premium over the general rights offer price. Eligible shareholders not taking up their full allocation, and ineligible shareholders, will receive NZ$0.17 per new share not taken up, with payment expected by 31 March 2026.

Settlement of new shares will enable trading to commence on both the NZX and the ASX. Genesis confirmed that these shares will have the same rights and status as existing ordinary shares. The company also continues as a leading NZ energy retailer with a strong mix of thermal and renewable generation assets, and a 46% stake in the Kupe Joint Venture.

What’s next for Genesis Energy?

With the equity raise completed, Genesis Energy will focus on deploying these new funds to support its ongoing operational and growth initiatives. The capital injection strengthens Genesis’ balance sheet and positions the business to further invest in its diverse generation portfolio.

Investors can expect updates on the company’s use of proceeds and strategic roadmap, particularly around renewable energy opportunities and customer growth in New Zealand’s competitive energy market.

Genesis Energy share price snapshot

Over the past 12 months, Genesis Energy shares have declined 4%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Genesis Energy completes NZ$400 million capital raise and rights offer appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• ASX 200 energy shares lead the market for a third week
• 6 rules for set-and-forget investing to fund your retirement goals
• Here are the top 10 ASX 200 shares today
• Viva Energy welcomes government boost to refinery support

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It’s been a rough stretch for some of the most talked-about ASX shares. But here’s the twist: while share prices have slid or stalled, broker optimism hasn’t. In fact, it’s surging.

Three ASX shares stand out right now: Mesoblast Ltd (ASX: MSB), Telix Pharmaceuticals Ltd (ASX: TLX), and Zip Co Ltd (ASX: ZIP). All three have had turbulent months. Yet analysts see massive upside, in some cases, more than a double from here.

Let’s break them down.

Mesoblast: Largely pre-profit

This ASX share has had a shaky start to the year, with the share price down about 25%. That’s nothing new for this high-risk biotech stock. Volatility comes with the territory.

Strengths? Mesoblast is targeting major unmet medical needs with its stem cell therapies. Regulatory progress and clinical milestones can be powerful catalysts. When sentiment turns, it can turn fast.

Weaknesses? It’s still largely pre-profit and heavily dependent on approvals. Delays or setbacks can hit the share price hard. Funding risk also lingers.

Analyst outlook: This is where things get interesting. Brokers have an average price target on the ASX share of $4.23 at the time of writing. That implies around 105% upside. In other words, analysts believe a doubling is firmly on the table if execution improves.

Telix: Pipeline gaining traction

Telix is the outlier here. It’s actually up about 13% this year. But zoom out and the picture changes — the ASX share is still down roughly 54% over 12 months.

Strengths? Telix is already generating revenue from its prostate cancer imaging product. It’s not just a story stock. Its pipeline in therapeutic radiopharmaceuticals is also gaining traction.

Weaknesses? Growth expectations are high, and any miss can disappoint. The company also operates in a complex regulatory and manufacturing environment.

Analyst outlook: Brokers remain firmly bullish. The average price target sits at $23.97, suggesting 88% upside. Even more striking, the most bullish target is $31.59 — a potential 148% gain. That’s serious conviction.

Zip: Cutting costs, improving margins

Zip has had the toughest run of the three. The buy now, pay later ASX share is down around 55% this year. Investor sentiment has been fragile.

Strengths? The company has been aggressively cutting costs and focusing on profitability. Its US business is showing resilience, and margins are improving.

Weaknesses? It’s still exposed to consumer spending cycles and credit risk. Competition in the BNPL space remains fierce. Market trust also needs rebuilding.

Analyst outlook: Despite all that, brokers are highly optimistic. The average price target is $4.21. That’s about 191% upside — nearly triple its current share price. Few ASX shares carry that kind of implied return.

Foolish Takeaway

These three ASX shares aren’t for the faint-hearted. Each carries risk. Each has burned investors recently.

But here’s the bottom line: brokers see significant mispricing. If even part of the bullish thesis plays out, the upside could be substantial.

For investors willing to stomach volatility, the ASX growth stocks could be worth a closer look.

The post 3 top ASX shares that could double in value from here appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Bell Potter says these ASX 200 stocks could rise 50%+
• 3 ASX 200 stocks screaming higher in this week’s sinking market
• 2 battered ASX growth shares that could double in value or more
• Could Telix shares be a millionaire-maker stock?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.